CN105250229B - 一种含吉法酯的药物组合物 - Google Patents
一种含吉法酯的药物组合物 Download PDFInfo
- Publication number
- CN105250229B CN105250229B CN201510669397.8A CN201510669397A CN105250229B CN 105250229 B CN105250229 B CN 105250229B CN 201510669397 A CN201510669397 A CN 201510669397A CN 105250229 B CN105250229 B CN 105250229B
- Authority
- CN
- China
- Prior art keywords
- composition
- parts
- gefarnate
- powder
- magnesium hydroxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- ZPACYDRSPFRDHO-ROBAGEODSA-N Gefarnate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C ZPACYDRSPFRDHO-ROBAGEODSA-N 0.000 title claims abstract description 44
- 229920001386 Gefarnate Polymers 0.000 title claims abstract description 44
- 229960003779 gefarnate Drugs 0.000 title claims abstract description 44
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- 239000000843 powder Substances 0.000 claims abstract description 34
- 239000000203 mixture Substances 0.000 claims abstract description 28
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 238000002156 mixing Methods 0.000 claims description 30
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 22
- 235000010489 acacia gum Nutrition 0.000 claims description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 17
- 238000007873 sieving Methods 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 14
- 229920002472 Starch Polymers 0.000 claims description 12
- 239000011734 sodium Substances 0.000 claims description 12
- 229910052708 sodium Inorganic materials 0.000 claims description 12
- 229940032147 starch Drugs 0.000 claims description 12
- 235000019698 starch Nutrition 0.000 claims description 12
- 239000008107 starch Substances 0.000 claims description 12
- 229920000084 Gum arabic Polymers 0.000 claims description 11
- 239000000205 acacia gum Substances 0.000 claims description 11
- 238000007796 conventional method Methods 0.000 claims description 11
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 11
- 239000000347 magnesium hydroxide Substances 0.000 claims description 11
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 11
- 239000000377 silicon dioxide Substances 0.000 claims description 11
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 9
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 9
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 9
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 9
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 9
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 9
- 244000215068 Acacia senegal Species 0.000 claims description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 6
- 239000007884 disintegrant Substances 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- 235000012239 silicon dioxide Nutrition 0.000 claims description 5
- 239000008109 sodium starch glycolate Substances 0.000 claims description 5
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 5
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 2
- 229960000913 crospovidone Drugs 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims description 2
- 238000003801 milling Methods 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- 235000012222 talc Nutrition 0.000 claims description 2
- 239000002994 raw material Substances 0.000 abstract description 9
- 239000000126 substance Substances 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 4
- 230000007547 defect Effects 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 description 27
- 239000011248 coating agent Substances 0.000 description 10
- 238000000576 coating method Methods 0.000 description 10
- 210000001156 gastric mucosa Anatomy 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 208000008469 Peptic Ulcer Diseases 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 208000011906 peptic ulcer disease Diseases 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 239000003223 protective agent Substances 0.000 description 3
- 208000007882 Gastritis Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- -1 isoprene compound Chemical class 0.000 description 2
- 230000004682 mucosal barrier function Effects 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229940126409 proton pump inhibitor Drugs 0.000 description 2
- 239000000612 proton pump inhibitor Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Natural products CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229940077716 histamine h2 receptor antagonists for peptic ulcer and gord Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
处方 | 羧甲淀粉钠 | 阿拉伯胶 | 氢氧化铝 | 氢氧化镁 | 二氧化硅 | HPMC |
处方1 | 7g | 53g | 152g | 58g | 100g | 40g |
处方2 | 10g | 39g | 98g | 38g | 65g | 5g |
处方3 | 11g | 54g | 196g | 75g | 129g | 10g |
处方4 | 11g | 113g | 245g | 94g | 161g | 15g |
处方5 | 14g | 215g | 367g | 141g | 242g | 20g |
处方6 | 16g | 320g | 490g | 188g | 323g | 24g |
阿拉伯胶用量 | 2份 | 4份 | 20份 | 25份 |
60min溶出度 | 77 | 65 | 59 | 48 |
崩解时限(min) | 2 | 4 | 10 | 18 |
Claims (16)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510669397.8A CN105250229B (zh) | 2015-10-13 | 2015-10-13 | 一种含吉法酯的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510669397.8A CN105250229B (zh) | 2015-10-13 | 2015-10-13 | 一种含吉法酯的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105250229A CN105250229A (zh) | 2016-01-20 |
CN105250229B true CN105250229B (zh) | 2020-07-03 |
Family
ID=55090371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510669397.8A Expired - Fee Related CN105250229B (zh) | 2015-10-13 | 2015-10-13 | 一种含吉法酯的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105250229B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002037727A (ja) * | 2000-07-26 | 2002-02-06 | Eisai Co Ltd | 脂溶性薬物を配合した速崩性固形製剤及びその製造方法 |
CN101472573A (zh) * | 2006-06-22 | 2009-07-01 | 株式会社钟化 | 含有还原型辅酶q10的组合物及其制备方法 |
CN109793898A (zh) * | 2019-03-15 | 2019-05-24 | 吉林大学 | 羟基磷灰石在片剂中的应用 |
-
2015
- 2015-10-13 CN CN201510669397.8A patent/CN105250229B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002037727A (ja) * | 2000-07-26 | 2002-02-06 | Eisai Co Ltd | 脂溶性薬物を配合した速崩性固形製剤及びその製造方法 |
CN101472573A (zh) * | 2006-06-22 | 2009-07-01 | 株式会社钟化 | 含有还原型辅酶q10的组合物及其制备方法 |
CN109793898A (zh) * | 2019-03-15 | 2019-05-24 | 吉林大学 | 羟基磷灰石在片剂中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN105250229A (zh) | 2016-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100836960B1 (ko) | 새로운 나이아신 제어방출형 제제 | |
EP2468264A1 (en) | Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it | |
KR101712524B1 (ko) | 타달라필 및 두타스테라이드를 포함하는 복합제제 조성물 및 그 제조방법 | |
CN101816641A (zh) | 一种奥美拉唑速释固体制剂及其制备方法 | |
US9114085B2 (en) | Modified release pharmaceutical compositions of dexlansoprazole | |
CA3121624A1 (en) | Methods for treating or preventing gout or hyperuricemia | |
CN109875972B (zh) | 一种奥美沙坦酯氨氯地平药物组合物 | |
CN104208039B (zh) | 一种萘普生埃索美拉唑镁肠溶制剂及制备方法 | |
KR101485421B1 (ko) | 이토프라이드 염산염을 함유하는 제어 방출성 경구 제제의 조성물 및 그의 제조방법 | |
CN101991561B (zh) | 氯桂丁胺组合物 | |
KR20220065997A (ko) | 라베프라졸 및 제산제를 포함하는 약제학적 복합제제 및 이의 제조방법 | |
CN105250229B (zh) | 一种含吉法酯的药物组合物 | |
CN106606486A (zh) | 一种比拉斯汀片及其制备方法 | |
JP2022544167A (ja) | ニトロキソリンを含む医薬組成物、ニトロキソリン経口固形錠剤、その調製方法、及びその使用 | |
CN103202820A (zh) | 一种稳定的兰索拉唑肠溶胶囊及其制备方法 | |
CN101756935A (zh) | 一种奥美拉唑胶囊及其制备方法 | |
CN108514550A (zh) | 含有醋酸阿比特龙的固体药物及其制备方法 | |
CN102370629B (zh) | 恩替卡韦液体胶囊及其制备方法 | |
CN102579453B (zh) | 一种治疗胃溃疡的复方制剂及其制备方法 | |
CN103202819A (zh) | 一种雷贝拉唑钠肠溶片及其制备方法 | |
CN108289849A (zh) | 莫沙必利与雷贝拉唑的复合制剂 | |
CN105816436A (zh) | 一种泮托拉唑肠溶微丸、泮托拉唑肠溶缓控释片剂及其制备方法 | |
KR101809886B1 (ko) | 소형화된 클래리트로마이신 경구투여 제제 | |
KR20110130872A (ko) | 결정형 염산 네비볼롤을 포함하는 약학 조성물 및 제조방법 | |
CN107224585B (zh) | 一种包含非甾体抗炎药和质子泵抑制剂的组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20160120 Assignee: Hangzhou Huadi Pharmaceutical Technology Co.,Ltd. Assignor: HANGZHOU HUADONG MEDICINE GROUP PHARMACEUTICAL RESEARCH INSTITUTE Co.,Ltd. Contract record no.: X2021330000100 Denomination of invention: A pharmaceutical composition containing GEFA ester Granted publication date: 20200703 License type: Common License Record date: 20210820 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200703 |